Managing the Course of Kidney Disease in Adults With Type 2 Diabetes: From the Old to the New

Abstract

Diabetic kidney disease (DKD) is a group of chronic kidney diseases that is associated with significant cardiovascular as well as all-cause morbidity and mortality. Although DKD is often progressive in nature, its evolution can be modified by intensive management of glycemia and blood pressure and inhibition of the renin-angiotensin-aldosterone system. This review provides an overview of how multifactorial interventions can provide renal protection and includes a discussion of the nonglycemic effects of incretin-based diabetes therapies (glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase 4 inhibitors) and sodium-glucose cotransporter-2 inhibitors within the kidney in patients with type 2 diabetes.

Keywords: DPP-4 inhibitors; GLP-1R agonists; SGLT2 inhibitors; agonistes des récepteurs GLP-1; blood pressure; diabetic kidney disease; glycemia; glycémie; inhibiteurs de la DPP-4; inhibiteurs du SGLT2; néphropathie diabétique; pression artérielle.